The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review
Abstract Background Despite the availability of vaccination, TBE (tick-borne encephalitis) remains a global public health problem. Therefore, the aim of our study was to assess the long-term efficacy of vaccinations against tick-borne encephalitis using vaccines available on the European market. Met...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-023-08562-9 |
| _version_ | 1797577868011634688 |
|---|---|
| author | Wojciech Miazga Katarzyna Wnuk Tomasz Tatara Jakub Świtalski Adrian Matera Urszula Religioni Mariusz Gujski |
| author_facet | Wojciech Miazga Katarzyna Wnuk Tomasz Tatara Jakub Świtalski Adrian Matera Urszula Religioni Mariusz Gujski |
| author_sort | Wojciech Miazga |
| collection | DOAJ |
| description | Abstract Background Despite the availability of vaccination, TBE (tick-borne encephalitis) remains a global public health problem. Therefore, the aim of our study was to assess the long-term efficacy of vaccinations against tick-borne encephalitis using vaccines available on the European market. Methods The analysis was conducted on the results of a systematic review conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. The search was performed in three databases, namely Medline (via PubMed), EMBASE (via Ovid), and the Cochrane Library database. The authors followed the PRISMA method and the selection of the articles was performed with two independent researchers. Results From a total of 199 citations, 9 studies were included in this review. According to the primary studies identified in the search, the efficacy of available anti-TBE vaccines ranges from 90.1% to 98.9%; however, in individuals above the age of 60, the protection wanes as early as one year after vaccination. Administration of a booster dose 3 years after completion of the basic vaccination schedule significantly extended the period of protection against TBE. Conclusions Anti-TBE vaccines available in Europe have a high level of efficacy. However, the level of protection against TBE is decreasing after vaccination. Therefore, in addition to the conventional schedule, booster vaccines should be administered every 5 years in individuals before the age of 60 and more frequently, e.g. every 3 years, in individuals aged 60 and beyond. |
| first_indexed | 2024-03-10T22:15:04Z |
| format | Article |
| id | doaj.art-268ab34ee5c84be4b3f2ca7b513c1e3b |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-10T22:15:04Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-268ab34ee5c84be4b3f2ca7b513c1e3b2023-11-19T12:28:59ZengBMCBMC Infectious Diseases1471-23342023-09-0123111110.1186/s12879-023-08562-9The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic reviewWojciech Miazga0Katarzyna Wnuk1Tomasz Tatara2Jakub Świtalski3Adrian Matera4Urszula Religioni5Mariusz Gujski6Department of Health Policy Programs, Department of Health Technology Assessment, Agency for Health Technology Assessment and Tariff SystemDepartment of Health Policy Programs, Department of Health Technology Assessment, Agency for Health Technology Assessment and Tariff SystemDepartment of Health Policy Programs, Department of Health Technology Assessment, Agency for Health Technology Assessment and Tariff SystemDepartment of Health Policy Programs, Department of Health Technology Assessment, Agency for Health Technology Assessment and Tariff SystemDepartment of Health Policy Programs, Department of Health Technology Assessment, Agency for Health Technology Assessment and Tariff SystemSchool of Public Health, Centre of Postgraduate Medical Education of WarsawDepartment of Public Health, Faculty of Health Sciences, Medical University of WarsawAbstract Background Despite the availability of vaccination, TBE (tick-borne encephalitis) remains a global public health problem. Therefore, the aim of our study was to assess the long-term efficacy of vaccinations against tick-borne encephalitis using vaccines available on the European market. Methods The analysis was conducted on the results of a systematic review conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. The search was performed in three databases, namely Medline (via PubMed), EMBASE (via Ovid), and the Cochrane Library database. The authors followed the PRISMA method and the selection of the articles was performed with two independent researchers. Results From a total of 199 citations, 9 studies were included in this review. According to the primary studies identified in the search, the efficacy of available anti-TBE vaccines ranges from 90.1% to 98.9%; however, in individuals above the age of 60, the protection wanes as early as one year after vaccination. Administration of a booster dose 3 years after completion of the basic vaccination schedule significantly extended the period of protection against TBE. Conclusions Anti-TBE vaccines available in Europe have a high level of efficacy. However, the level of protection against TBE is decreasing after vaccination. Therefore, in addition to the conventional schedule, booster vaccines should be administered every 5 years in individuals before the age of 60 and more frequently, e.g. every 3 years, in individuals aged 60 and beyond.https://doi.org/10.1186/s12879-023-08562-9EncephalitisTick-borneVaccinesImmunizationTBE |
| spellingShingle | Wojciech Miazga Katarzyna Wnuk Tomasz Tatara Jakub Świtalski Adrian Matera Urszula Religioni Mariusz Gujski The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review BMC Infectious Diseases Encephalitis Tick-borne Vaccines Immunization TBE |
| title | The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review |
| title_full | The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review |
| title_fullStr | The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review |
| title_full_unstemmed | The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review |
| title_short | The long-term efficacy of tick-borne encephalitis vaccines available in Europe - a systematic review |
| title_sort | long term efficacy of tick borne encephalitis vaccines available in europe a systematic review |
| topic | Encephalitis Tick-borne Vaccines Immunization TBE |
| url | https://doi.org/10.1186/s12879-023-08562-9 |
| work_keys_str_mv | AT wojciechmiazga thelongtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT katarzynawnuk thelongtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT tomasztatara thelongtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT jakubswitalski thelongtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT adrianmatera thelongtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT urszulareligioni thelongtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT mariuszgujski thelongtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT wojciechmiazga longtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT katarzynawnuk longtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT tomasztatara longtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT jakubswitalski longtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT adrianmatera longtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT urszulareligioni longtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview AT mariuszgujski longtermefficacyoftickborneencephalitisvaccinesavailableineuropeasystematicreview |